Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
Identifieur interne : 001D25 ( Main/Curation ); précédent : 001D24; suivant : 001D26Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
Auteurs : Bonnie P. Hersh [États-Unis] ; Nancy L. Earl [États-Unis] ; Robert A. Hauser [États-Unis] ; Mark Stacy [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-05-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Delayed-Action Preparations, Dopamine Agonists (therapeutic use), Double-Blind Method, Evaluation scale, Female, Fluctuations, Human, Humans, Indoles (therapeutic use), Male, Movement Disorders (diagnosis), Movement Disorders (epidemiology), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Release, Ropinirole, Severity of Illness Index, Treatment, Treatment Outcome, Unified Parkinson's Disease Rating Scale, efficacy, motor fluctuations, ropinirole prolonged release.
- MESH :
- chemical , therapeutic use : Dopamine Agonists, Indoles.
- chemical : Delayed-Action Preparations.
- diagnosis : Movement Disorders.
- drug therapy : Parkinson Disease.
- epidemiology : Movement Disorders, Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Severity of Illness Index, Treatment Outcome.
Abstract
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23040
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B00
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B00
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A04
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001828
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001828
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001917
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002B74
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002B74
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002B74
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002161
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B21
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :002198
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A91
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002678
Links to Exploration step
ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23040</idno>
<idno type="url">https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B00</idno>
<idno type="wicri:Area/Istex/Curation">000B00</idno>
<idno type="wicri:Area/Istex/Checkpoint">000A04</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20461810</idno>
<idno type="wicri:Area/PubMed/Corpus">001828</idno>
<idno type="wicri:Area/PubMed/Curation">001828</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001917</idno>
<idno type="wicri:Area/Ncbi/Merge">002B74</idno>
<idno type="wicri:Area/Ncbi/Curation">002B74</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002B74</idno>
<idno type="wicri:Area/Main/Merge">002161</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0288331</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B21</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002198</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A91</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:Area/Main/Merge">002678</idno>
<idno type="wicri:Area/Main/Curation">001D25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts</wicri:regionArea>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-05-15">2010-05-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="927">927</biblScope>
<biblScope unit="page" to="931">931</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno>
<idno type="DOI">10.1002/mds.23040</idno>
<idno type="ArticleID">MDS23040</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Delayed-Action Preparations</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Evaluation scale</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Male</term>
<term>Movement Disorders (diagnosis)</term>
<term>Movement Disorders (epidemiology)</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Release</term>
<term>Ropinirole</term>
<term>Severity of Illness Index</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>Unified Parkinson's Disease Rating Scale</term>
<term>efficacy</term>
<term>motor fluctuations</term>
<term>ropinirole prolonged release</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Echelle d'évaluation</term>
<term>Fluctuation</term>
<term>Homme</term>
<term>Libération</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Ropinirole</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2010:Hersh B:early:treatment:benefits"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0288331</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0288331 INIST</idno>
<idno type="RBID">Pascal:10-0288331</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B21</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002198</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A91</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:Area/Main/Merge">002678</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Early Treatment Benefits of Ropinirole Prolonged Release in Parkinson's Disease Patients with Motor Fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Harvard Vanguard Medical Associates</s1>
<s2>Boston Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Clinical Neurosciences, GlaxoSmithKline</s1>
<s2>Research Triangle Park, North Carolina</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Neurology, University, of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Division of Neurology, Department of Medicine, Duke University</s1>
<s2>Durham, North Carolina</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evaluation scale</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Release</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Traitement</term>
<term>Ropinirole</term>
<term>Libération</term>
<term>Homme</term>
<term>Fluctuation</term>
<term>Echelle d'évaluation</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, - 0.5 ; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23040</idno>
<idno type="url">https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B00</idno>
<idno type="wicri:Area/Istex/Curation">000B00</idno>
<idno type="wicri:Area/Istex/Checkpoint">000A04</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20461810</idno>
<idno type="wicri:Area/PubMed/Corpus">001828</idno>
<idno type="wicri:Area/PubMed/Curation">001828</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001917</idno>
<idno type="wicri:Area/Ncbi/Merge">002B74</idno>
<idno type="wicri:Area/Ncbi/Curation">002B74</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002B74</idno>
<idno type="wicri:Area/Main/Merge">002161</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts</wicri:regionArea>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-05-15">2010-05-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="927">927</biblScope>
<biblScope unit="page" to="931">931</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno>
<idno type="DOI">10.1002/mds.23040</idno>
<idno type="ArticleID">MDS23040</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Delayed-Action Preparations</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Male</term>
<term>Movement Disorders (diagnosis)</term>
<term>Movement Disorders (epidemiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson's disease</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
<term>Unified Parkinson's Disease Rating Scale</term>
<term>efficacy</term>
<term>motor fluctuations</term>
<term>ropinirole prolonged release</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001D25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2 |texte= Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations }}
This area was generated with Dilib version V0.6.23. |